Minakem-flap
Minakem-flap

Find FDA Investigational New Drug (IND) Submissions for Neurology in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PMN310

            Therapeutic Area: Neurology Product Name: PMN310

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fenway Sports Group

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 22, 2021

            Details:

            ProMIS plans to accelerate progress toward a number of top priorities, including; Advancing the PMN310 monoclonal antibody into clinical testing; Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): YTX-7739

            Therapeutic Area: Neurology Product Name: YTX-7739

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 09, 2021

            Details:

            YTX-7739 prevented motor function deficits in the diseased mice after four months of YTX-7739 oral dosing compared to placebo-treated mice. YTX-7739 demonstrates pharmacological, physiological, and behavioral pre-clinical proof of concept in in vivo model.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amniotic fluid derived stem cells

            Therapeutic Area: Neurology Product Name: ImmCelz

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2021

            Details:

            Creative Medical Technology Holdings reported that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz IND for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MTK-458

            Therapeutic Area: Neurology Product Name: MTK-458

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 02, 2021

            Details:

            Under the terms of the agreement, Mitokinin will receive an upfront payment and will continue developing its PINK1 activator program of MTK-458 through completion of IND enabling studies for Mitokinin's lead compound.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PBFT02

            Therapeutic Area: Neurology Product Name: PBFT02

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: University of Pennsylvania

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2021

            Details:

            Passage Bio is developing PBFT02 to treat FTD-GRN as a single dose delivered via intra-cisterna magna (ICM) injection. The gene therapy utilizes an AAV1 viral vector to deliver a modified DNA encoding the GRN gene to a patient's cells.